Comparing the current results to its competitors, Lannett Inc reported Revenue increase in the 3 quarter 2023 by 1.41 % year on year, while most of its competitors have experienced contraction in revenues by -13.54 %, achieved in the same quarter.
Lannett Company Inc, slower than the average decrease reported by the company's competitors of -36.78 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -36.78 %
With modest revenue growth of 1.41 % within Overall company, Lannett Company Inc managed to improve its market share within this segment to approximately 0.14 %. << More on LCINQ Market Share.
*Market share is calculated based on total revenue.
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Amneal Pharmaceuticals Inc operates as a fully integrated pharmaceutical company, primarily focused on the development, manufacturing, and distribution of generic and specialty pharmaceutical products. Their business model revolves around identifying market opportunities, conducting research to develop cost-effective formulations, and leveraging their expansive manufacturing capabilities to produce and distribute a wide range of pharmaceuticals to customers globally. Additionally, they aim to provide high-quality products at competitive prices while continuously investing in research and development to expand their product portfolio.
Amphastar Pharmaceuticals Inc's business model revolves around developing, manufacturing, and marketing specialty pharmaceutical products. The company focuses on niche markets and primarily produces finished dosage form and active pharmaceutical ingredients (APIs) for injectable, inhalation, and intranasal delivery systems. Amphastar aims to provide innovative and cost-effective solutions for complex therapeutic needs, while maintaining regulatory compliance and ensuring the highest standard of quality.
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Sources:
Lannett Company Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lannett Company Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
